42 results
8-K
EX-99.2
AGIO
Agios Pharmaceuticals Inc
8 Jan 24
Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio
7:58am
40% Achieved Transfusion Independence endpoint in open-label Phase 2a study Expect to initiate Phase 2b study of AG-946 in mid-2024 ~75-80k patients
DEFA14A
ar26qa3g jg
12 Jan 21
Additional proxy soliciting materials
5:15pm
DEFA14A
dizqr 1l4q60l7i
23 Dec 20
Additional proxy soliciting materials
4:52pm
DEFA14A
gkd8m0kjbwmgk3vbwte
21 Dec 20
Additional proxy soliciting materials
5:23pm
DEFA14A
EX-99.2
6e4jhi gmxy8dd9
21 Dec 20
Additional proxy soliciting materials
7:10am
DEFA14A
EX-99.1
gv0s3m9ps8rb388f8
21 Dec 20
Additional proxy soliciting materials
7:10am
8-K
EX-99.1
duomg
21 Dec 20
Regulation FD Disclosure
7:04am